Dr Steve Pereira

Dr Steve PereiraTel: 020 3447 9229
Fax: 020 3447 9218
Email: steve.pereira@uclh.nhs.uk

University College Hospital

Hepato Pancreato Bilary Cancers HPB, Endoscopy Unit, Pancreatobiliary service, Gastrointestinal services

Professional background

Steve Pereira studied science and medicine at University of New South Wales, Sydney, with postgraduate training in gastroenterology and hepatology mainly at Guy’s and King’s College hospitals, London and advanced endoscopy training in Paris, Amsterdam and Indianapolis. He has been a consultant at University College Hospital since 2000, and is also a Reader in Hepatology and Gastroenterology at University College London and an honorary consultant at the Royal Free Hospital.

His clinical and research interests centre on the causes, early diagnosis and treatment of liver and pancreatic cancer, as well as benign biliary and pancreatic diseases. These conditions represent a significant number of patients referred for specialist opinion to UCLH, and the activity of the research group is linked closely with the clinical hepatopancreaticobiliary service at UCLH and the Royal Free. He is currently Chairman of the British Society of Gastroenterology Pancreatic Section,  previous Chairman of the North-East Thames Gastroenterology Training Committee and past President of the Pancreatic Society of GB&I. He also serves on the European Society of Gastrointestinal Endoscopy Education Committee and the British Society of Gastroenterology Council.

Research interests

  • Serum biomarkers of pancreaticobiliary malignancy
  • Optical diagnostics and treatment monitoring
  • Cystic tumours of the pancreas
  • Photodynamic therapy
  • Primary sclerosing cholangitis
  • Immunology of hepatocellular and pancreatic cancer
  • Serum and bile proteomics in pancreaticobiliary malignancy
  • Inhibitors of DNA replication in pancreatic cancer
  • Symptom identification in pancreatic malignancy
  • Sphincter of Oddi dysfunction
  • Complications of chronic pancreatitis


Approximately 150 original papers, reviews and book chapters. Selected publications since 2010 below:

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-81.

Behboudi S, Pereira SP. Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma. World J Hepatol 2010; 27: 256-60.
Vasiliadis KV, Pereira SP. Diagnosis and management of GI stromal tumors by EUS-FNA. Gastrointest Endosc 2010; 71; 1102.

Bridgewater J, Pereira SP. Cancers of the gastrointestinal tract. In: Warrell DA, Cox TM, Firth JD, Benz EJ, eds. Oxford Textbook of Medicine (5th Edition). Oxford University Press, 2010 (http://otm.oxfordmedicine.com).

Member Guideline Development Group. NICE Clinical Guidance 100. Alcohol-use disorders. Diagnosis and clinical management of alcohol-related physical complications National Institute for Health and Clinical Excellence, June 2010 (268 pages).

Huggett MT, Ghaneh P, Pereira SP. Drainage and bypass procedures for palliation of malignant diseases of the upper gastrointestinal tract. Clin Onc 2010; 22: 755-63.
Samkoe KS, Chen AA, Rizvi I, O'Hara JA, Hoopes PJ, Pereira SP, Hasan T, Pogue PW. Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models. Internat J Rad Onc Biol Phys 2010; 1: 251-9.

Pereira SP, Ayaru L, Ackroyd R, Mitton D, Fullarton G, Zammit M, Butruk E, Grzebieniak Z, Messmann H, Ortner MA, Gao L, Sayyarpour F, Trinh M, Spénard J. Pharmacokinetics of porfimer sodium after repeated administrations 30 to 45 days apart to patients undergoing photodynamic therapy. Aliment Pharmacol Therap 2010; 32: 821-7.

Horsfall L, Rait G, Walters K,  Swallow DM, Pereira SP, Nazareth I, Petersen I. Serum bilirubin and risk of respiratory disease and death. JAMA 2011; 305: 691-7.

Sugumar A, Levy MJ, Kamisawa T, Webster GJM, Kim M-H, Enders F, Amin Z, Baron TH, Chapman MJ, Church NI, Clain JE, Egawa N, Johnson GJ, Okazaki K, Pearson RK, Pereira SP, Petersen BT, Read S, Sah RP,  Sandanayake NS, Takahashi N, Topazian MD, Uchida K, Vege SS, Chari ST. Endoscopic retrograde pancreatography criteria to diagnose autoimmune pancreatitis: an international multicentre study. Gut 2011; 60: 666-70.

Wadsworth CA, Dixon PH, Wong JH, Chapman MH, McKay SC, Sharif A, Spalding DR, Pereira SP, Thomas H, Taylor-Robinson SD, Whittaker J, Williamson C, Khan SA. Genetic factors in the pathogenesis of cholangiocarcinoma. Dig Dis 2011; 29: 93-7.
Huggett MT, Pereira SP. Diagnosing and managing pancreatic cancer. Practitioner 2011; 255: 21-5.

Skipworth JR, OldeDamink SW, Imber C, Bridgewater J, Pereira SP, Malago M. Surgical, neo-adjuvant and adjuvant management strategies for cholangiocarcinoma. Aliment Pharm Ther 2011; 34: 1063-70.

Matull WR, Dhar DK, Ayaru L, Sandanayake NS, Chapman MH, Dias A, Bridgewater J, Webster GJM, Bong JJ, Davidson BR, Pereira SP. R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer. Liv Internat 2011; 31: 99-107.

Skipworth JRA, Morkane C, West NJ, Raptis DA, Deheragoda M, Imber C, Oldedamink S, Pereira SP, Malago M, Phillips RKS, Clark SK, Shankar A. Pancreaticoduodenectomy for advanced duodenal and ampullary adenomatosis in familial adenomatous polyposis. HPB 2011; 13: 342-9.

Friend E, Yadegarfar G, Byrne C, Johnson CD, Sezer O, Pucciarelli S, Pereira SP, Chie W-C, Banfield A, Ramage J, on behalf of the EORTC Quality of Life Group. Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21. Br J Cancer 2011; 104: 587-92.

Boswell S, Sharif S, Alisa A, Pereira SP, Williams R, Behboudi S. Induction of latency-associated peptide (transforming growth factor -β) expression on CD4+ T cells reduces Toll-like receptor 4 ligand-induced tumour necrosis factor-α production in a transforming growth factor-β dependent manner. Immunology 2011; 133: 278-87.

Kalaitzakis E, Levy M, Kamisawa T, Johnson GJ, Baron TH, Topazian MD, Takahashi N, Kanno A, Okazaki K, Egawa N, Uchida K, Sheikh K, Amin Z, Shimosegawa T,  Sandanayake NS, Church NI, Chapman MH, Pereira SP, Chari S, Webster GJM.

Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from PSC or cholangiocarcinoma. Clin Gastroenterol Hepatol 2011; 9: 100-3.

Chapman MH, Sandanayake NS, Andreola F, Dhar DK, Webster GJ, Dooley JS, Pereira SP. Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer. A case control study. J Clin Exp Hepatol 2011; 1: 6-12.

Celli JP, Solban N, Liang A, Pereira SP, Hasan T. Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. Lasers Surg Med 2011 (in press)

Cahen DL, Gouma DJ, Laramée P, Nio Y, Rauws EAJ, Boermeester MA, Busch OR, Fockens P, Kuipers EJ, Pereira SP, Wonderling D, Dijkgraaf MGW, Bruno MJ. Endoscopic versus surgical drainage of the pancreatic duct in chronic pancreatitis; long-term outcome. Gastroenterology 2011; 141: 1690-5.

Sandanayake NS, Sinclair J, Andreola F, Chapman MH, Xue A, Webster GJ, Clarkson  A, Gill A, Norton ID, Smith RC, Timms JF, Pereira SP. A combination of serum leucine-rich alpha-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Ca 2011; 105: 1370-8.

Navani N, Kocjan G, Falzon M, Capitanio A, Pereira SP, Janes SM. The learning curve for EBUS-TBNA. Thorax 2011; 66: 352-3.

Lytras D, Kalaitzakis E, Webster GJ, Imber CJ, Amin Z, Rodriguez-Justo M, Pereira SP, OldeDamink W, Malago M. Cholangiocarcinoma or autoimmune IgG4 cholangitis: how feasible is it to avoid unnecessary surgical interventions? Ann Surg 2011 (in press).
Skipworth J, Shankar A, Pereira SP. Managing acute and chronic pancreatitis. Practitioner 2010; 254: 23-7.

Baddeley RN, Skipworth JR, Pereira SP. Acute pancreatitis. Medicine 2011; 39: 108-15.
Wadsworth CA, Dixon PH, Wong JH, Chapman MH, McKay SC, Sharif A, Spalding DR, Pereira SP, Thomas H, Taylor-Robinson SD, Whittaker J, Williamson C, Khan SA.

Genetic factors in the pathogenesis of cholangiocarcinoma. Dig Dis 2011; 29: 93-7.
Chapman MH, Tidswell R, Dooley JS, Sandanayake NS, Cerec V,  Deheragoda M, Lee AJ, Swanton C, Andreola F, Pereira SP. Whole genome RNA expression profiling of endoscopic biliary brushings provides data suitable for biomarker discovery in cholangiocarcinoma. J Hepatol 2011 (in press).

Webster GJM, Pereira SP. Diagnostic & Interventional ERCP. In: Weinstein WM, Hawkey, CJ, Bosch J. Gastroenterology and Hepatology: the Modern Clinician’s Guide. Elsevier Science, London, 2012 (in press).

Khan SA, Davidson BR, Goldin R, Pereira SP, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2012 (in press).

GMC/GDC number: 3515969